Refractory Diffuse Large B-Cell Lymphoma Clinical Trials in Chicago, Illinois

5 studies are recruiting for refractory diffuse large b-cell lymphoma in Chicago, Illinois right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma

   This phase I trial tests the safety, side effects, and best dose of nivolumab in combination with ASTX727 in treating B-cell lymphoma that has come back (relapsed) or does not respond to treatment (refractory). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune …

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Chicago Comprehensive Cancer Center, Chicago, Illinois

   Locations

   9 in total

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT05272384 on ClinicalTrials.gov

2. Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma

   This phase II trial tests how well venetoclax, ibrutinib, prednisone, obinutuzumab, and Revlimid® (ViPOR) works in treating patients with CD10 negative diffuse large B-cell lymphoma (DLBCL) and high-grade lymphoma with MYC and BCL2 rearrangements that has come back after a period of improvement (re…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Northwestern University, Chicago, Illinois

   Locations

   96 in total

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT06649812 on ClinicalTrials.gov

3. Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma

   This phase I trial evaluates the side effects and usefulness of axicabtagene clioleucel (a CAR-T therapy) and find out what effect, if any, it has on treating patients with HIV-associated aggressive B-cell non-Hodgkin lymphoma that has come back (relapsed) or not responded to treatment (refractory)…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Illinois at Chicago, Chicago, Illinois

   Locations

   7 in total

   Run by

   AIDS Malignancy Consortium

   See if you can join NCT05077527 on ClinicalTrials.gov

4. Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

   This phase II trial tests whether mosunetuzumab and/or polatuzumab vedotin helps benefit patients who have received chemotherapy (fludarabine and cyclophosphamide) followed by chimeric antigen receptor (CAR) T-cell therapy (tisagenlecleucel, axicabtagene ciloleucel, or lisocabtagene maraleucel) for…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   University of Illinois, Chicago, Illinois

   Locations

   87 in total

   Run by

   SWOG Cancer Research Network

   See if you can join NCT05633615 on ClinicalTrials.gov

5. Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment

   This phase 2 trial studies the side effects and best dose of tazemetostat and zanubrutinib in combination with tafasitamab and lenalidomide, and to see how well these combinations work in treating patients with large B-cell lymphoma that returned or did not respond to earlier treatment. Tazemetosta…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   University of Illinois, Chicago, Illinois

   Locations

   104 in total

   Run by

   SWOG Cancer Research Network

   See if you can join NCT05890352 on ClinicalTrials.gov